Skip to Main Content
Table 2—

The effect of baseline strata on the relative risk of developing type 2 diabetes over 4 years in patients, irrespective of treatment

VariableHazard ratio95% CIP
Treatment group: orlistat versus placebo 0.63 (0.46–0.87) 0.0052 
Glucose tolerance: impaired versus normal 10.60 (7.30–15.40) <0.0001 
Sex: male versus female 1.41 (1.02–1.96) 0.0390 
Age (years): >44* vs. ≤44 1.44 (1.02–2.04) 0.0383 
BMI (kg/m2): ≥37 vs. <37* 1.36 (0.97–1.91) 0.0726 
VariableHazard ratio95% CIP
Treatment group: orlistat versus placebo 0.63 (0.46–0.87) 0.0052 
Glucose tolerance: impaired versus normal 10.60 (7.30–15.40) <0.0001 
Sex: male versus female 1.41 (1.02–1.96) 0.0390 
Age (years): >44* vs. ≤44 1.44 (1.02–2.04) 0.0383 
BMI (kg/m2): ≥37 vs. <37* 1.36 (0.97–1.91) 0.0726 
*

Median.

Close Modal

or Create an Account

Close Modal
Close Modal